Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What to do with an abnormal PSA test.

Stacy Loeb1, William J Catalona

  • 1Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

The Oncologist
|April 2, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Availability, quality, and understandability of English and Spanish-language YouTube content on PSMA PET imaging for prostate cancer.

Clinical imaging·2026
Same author

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

The burden of Peyronie's disease on the female partner: a qualitative study.

The journal of sexual medicine·2026
Same author

Intimacy After Diagnosis: Navigating Sexual Health Conversations and Disparities Among Cancer Survivors.

The American journal of hospice & palliative care·2026
Same author

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Cancer·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Prostate-specific antigen (PSA) has been a cornerstone of prostate cancer screening for over ten years. This review details the evolution of PSA screening, including new methods for informed clinical use.

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate-specific antigen (PSA) has been utilized for prostate cancer screening for over a decade.
  • Screening protocols have evolved, incorporating lower PSA thresholds, PSA isoforms, and PSA kinetics.

Purpose of the Study:

  • To review the historical development of prostate cancer screening using PSA.
  • To offer clinical insights into the effective application of PSA and related measurements.

Main Methods:

  • Literature review of prostate cancer screening advancements.
  • Analysis of PSA testing, including total PSA, isoforms, and kinetics.

Main Results:

  • Prostate cancer screening with PSA has undergone significant refinement over time.

Related Experiment Videos

  • Adjunctive PSA measurements offer enhanced diagnostic information.

    • Conclusions:

    • Informed use of PSA and its related markers is crucial for effective prostate cancer screening.
    • Continued evolution of PSA-based screening improves clinical decision-making.